Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO™ MicroShunt
Glaukos (NYSE: GKOS) said it completed patient enrollment in a U.S. 510(k) pivotal study of the PRESERFLO MicroShunt for adult primary open-angle glaucoma patients whose IOP was inadequately controlled after prior treatment. The single-arm trial enrolled at least 110 patients. Glaukos plans to use results to support a future FDA marketing submission.
How this was made
The 30-second read
Why it matters
Completion of enrollment (target at least 110 patients across U.S. and Canada) advances the program into patient follow-up, with results intended to support a future FDA marketing submission. The next tradable catalyst is the 12-month primary endpoint readout and any regulatory interactions.
Market read
This is a concrete clinical-program milestone that can modestly improve regulatory de-risking, but it is not an efficacy or safety data release.
What to watch
The trial is single-arm and the primary endpoint is a specific IOP reduction without increased medication classes; investors may discount the milestone until follow-up results and any FDA questions are addressed.
Background
Glaukos is evaluating the PRESERFLO MicroShunt in a U.S. 510(k) pivotal study for adult POAG patients who failed prior medical and surgical treatment.
Ticker impact
Glaukos says it completed patient enrollment in its U.S. 510(k) pivotal study for the PRESERFLO MicroShunt, targeting at least 110 patients.
Moderate positive bias, with follow-through dependent on subsequent follow-up data and FDA interaction.
The article discloses a fresh clinical-program milestone (enrollment target met) and reiterates the primary endpoint and intent to use results for an FDA submission, but it does not provide new efficacy/safety results.
Market effects
Supports the broader glaucoma device/MIGS narrative by advancing a key regulatory step for an ab-externo drainage platform.
Primarily U.S. regulatory pathway progress, with potential knock-on sentiment for North American ophthalmic medtech peers.
Limited direct global impact since the milestone is U.S. 510(k) enrollment, though it reinforces confidence in the device’s commercialization trajectory in other markets.
Counterpoint
Enrollment completion may not move the stock much if investors are focused on 12-month outcomes and FDA feedback rather than enrollment status.
Key entities
- companyGlaukos Corporation
Sponsor of the PRESERFLO MicroShunt U.S. 510(k) pivotal study; exclusive U.S. rights under a Santen license.
- productPRESERFLO MicroShunt
Ab-externo glaucoma drainage device designed to lower intraocular pressure; primary endpoint assessed at 12 months.
- partnerSanten Pharmaceutical Co., Ltd.
Licensor granting Glaukos exclusive development and commercialization rights in multiple markets.
